Aclarion, Inc. (ACON)
ACON moved a median of -1.41% 30 minutes after news, and -1.63% by the close. How ACON actually reacts to news — the realized, point-in-time move the market made, measured across 265 labeled events over the last three years with zero look-ahead.
ACON’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | -0.29% | 35% | 246 |
| 30-min | -1.41% | 36% | 263 |
| 60-min | -1.35% | 32% | 264 |
| to close | -1.63% | 42% | 265 |
| Middle 50% of ACON reactions | -3.25% to +1.23% |
|---|---|
| Median reaction (30-min) | -1.41% |
| Measured reactions | 265 |
Half of all Aclarion, Inc. news events land between -3.25% and +1.23% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when ACON moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ACON's baseline. Nothing else.
Recent ACON events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Aclarion to Present at the 20th Annual LD Micro Main Event | Press release | GlobeNewswire | — | -4.46% | |
| Aclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate Enrollment | Press release | GlobeNewswire | +0.00% | -2.12% | |
| Aclarion Welcomes NYU Langone Health to CLARITY Trial Network, Now Enrolling at Eleven Sites | Press release | GlobeNewswire | — | -2.86% | |
| Aclarion Announces Addition of University of Arizona College of Medicine – Phoenix as CLARITY Trial Site | Press release | GlobeNewswire | -3.62% | -2.54% | |
| Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process | Press release | GlobeNewswire | +1.44% | +0.00% | |
| Form 10-Q Aclarion, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -1.28% | +0.43% | |
| Aclarion Announces Nociscan® Now Available at Goodman Campbell Brain & Spine at Ascension St. Vincent, First Site in Indiana to Offer the Technology | Press release | GlobeNewswire | -0.63% | -0.42% | |
| Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026 | Press release | GlobeNewswire | -1.37% | -7.57% | |
| Aclarion Announces Presentation of Two Abstracts Highlighting Nociscan’s Growing Role in Real-World Clinical Practice | Press release | GlobeNewswire | -3.37% | -3.79% | |
| Form S-8 Aclarion, Inc. | SEC filing · Form S-8 | SEC EDGAR | -0.68% | -1.69% | |
| Aclarion Announces Texas Spine Care Center as New CLARITY Site | Press release | GlobeNewswire | +2.26% | -3.55% | |
| Aclarion to Present at the Planet MicroCap Las Vegas Powered by MicroCapClub | Press release | GlobeNewswire | — | -2.01% | |
| Aclarion Partners with PRIA Healthcare to Advance Reimbursement and Commercial Adoption of Its AI-Powered Nociscan Platform | Press release | GlobeNewswire | -1.53% | -0.31% | |
| Aclarion Rejects Echo Lake Capital’s Unsolicited Acquisition Proposal | Press release | GlobeNewswire | -0.14% | -4.27% | |
| Aclarion Stockholders Approve All Proposals at 2026 Annual Meeting | Press release | GlobeNewswire | -0.14% | -4.27% | |
| Form 8-K Aclarion, Inc. For: Jun 04 | SEC filing · Form 8-K | SEC EDGAR | -1.15% | +2.29% | |
| Aclarion Adds Institute of Neuro Innovation to Support Nociscan Growth and Real-World Evidence Generation | Press release | GlobeNewswire | -0.58% | +1.75% | |
| Aclarion Technology Demonstrates Potential Beyond Surgical Planning in New Immune-Biomarker Study | Press release | GlobeNewswire | -2.38% | +0.30% | |
| Aclarion, Inc. Comments on Echo Lake Capital’s Letter and Unsolicited Proposal | Press release | GlobeNewswire | +1.32% | -6.67% | |
| Echo Lake Capital Offers To Acquire Aclarion Inc. | Press release | ACCESS Newswire | +0.00% | -0.63% | |
| Form 10-Q Aclarion, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -0.30% | -3.01% | |
| Aclarion Announces Addition of First Private Practice Site in Los Angeles into CLARITY Trial to Further Accelerate Enrollment | Press release | GlobeNewswire | +0.00% | -4.53% | |
| Aclarion Announces Inducement Grant to New Commercial Director, Western U.S. | Press release | GlobeNewswire | -0.31% | +2.18% | |
| Aclarion Announces Second Commercial Agreement with Weill Cornell Medicine | Press release | GlobeNewswire | +0.92% | -2.14% | |
| Aclarion Delivers Strong Q1 2026 Results with 196% Annual Scan Volume Growth Reflecting Accelerating Clinical Adoption | Press release | GlobeNewswire | +0.00% | +0.61% | |
| Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued Adoption of Nociscan | Press release | GlobeNewswire | +1.83% | +2.74% | |
| Form DEF 14A Aclarion, Inc. For: Jun 04 | SEC filing · Form DEF | SEC EDGAR | +1.83% | +2.74% | |
| Aclarion Announces $2.5 Million Stock Repurchase Plan | Press release | GlobeNewswire | -0.13% | +0.27% | |
| Form 8-K Aclarion, Inc. For: Apr 21 | SEC filing · Form 8-K | SEC EDGAR | -0.13% | +0.27% | |
| Aclarion Secures U.S. Patent Advancing Scalable, AI-Driven Assessment of Chronic Low Back Pain | Press release | GlobeNewswire | +0.47% | +4.73% | |
| Aclarion Receives Pinnacle Award for AI Innovation | Press release | GlobeNewswire | +0.00% | -1.25% | |
| Aclarion Announces Agreement with Weill Cornell Medicine | Press release | GlobeNewswire | -2.44% | -3.25% | |
| Aclarion Highlights Growing Adoption of Nociscan at The London Clinic with New Physician Video | Press release | GlobeNewswire | — | +4.55% | |
| Form PRE 14A Aclarion, Inc. For: Jun 04 | SEC filing · Form PRE | SEC EDGAR | -3.99% | -6.06% | |
| Echo Lake Capital Calls for the Resignation of David Neal From the Board of Directors of Aclarion Inc. | Press release | ACCESS Newswire | +3.29% | +7.14% | |
| Aclarion Publishes CEO Shareholder Letter Highlighting Strategic Progress and 2026 Catalysts | Press release | GlobeNewswire | +1.56% | +1.88% | |
| Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan | Press release | GlobeNewswire | +1.56% | +1.88% | |
| Form 8-A12B Aclarion, Inc. | SEC filing · Form 8-A12B | SEC EDGAR | +0.16% | -0.31% | |
| Form 8-K Aclarion, Inc. For: Mar 19 | SEC filing · Form 8-K | SEC EDGAR | +0.16% | -0.31% | |
| Form 10-K Aclarion, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.56% | +1.88% | |
| Aclarion to Participate in the 38th Annual ROTH Conference, Highlighting Key 2026 Catalysts and Strong Balance Sheet | Press release | GlobeNewswire | +0.67% | +0.62% | |
| Aclarion CEO Brent Ness to Attend LSI USA 2026 | Press release | GlobeNewswire | +0.00% | -3.48% | |
| Aclarion Publishes 2026 Shareholder Letter from the Chairman | Press release | GlobeNewswire | -1.11% | -12.59% | |
| Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation | Press release | GlobeNewswire | +1.57% | -1.74% | |
| Aclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028 | Press release | GlobeNewswire | -3.76% | -9.68% | |
| Form 8-K Aclarion, Inc. For: Jan 09 | SEC filing · Form 8-K | SEC EDGAR | -3.76% | -9.68% | |
| Form 8-K Aclarion, Inc. For: Jan 08 | SEC filing · Form 8-K | SEC EDGAR | -6.22% | -19.66% | |
| Aclarion Provides 2025 Update and 2026 Corporate Outlook | Press release | GlobeNewswire | +0.90% | +0.00% | |
| Aclarion Announces First Patient Enrollments at Two Additional CLARITY Trial Sites and Provides Guidance on Expected Availability of Initial Data | Press release | GlobeNewswire | +0.00% | +2.29% | |
| Aclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS) | Press release | GlobeNewswire | +11.91% | -3.27% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ACON section they belong to.
Where else ACON is measured.
ACON earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Aclarion, Inc.'s median reaction calculated?
Every labeled ACON news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 265 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 36% of ACON's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does ACON's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.